CA2547863A1 - Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy - Google Patents
Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy Download PDFInfo
- Publication number
- CA2547863A1 CA2547863A1 CA002547863A CA2547863A CA2547863A1 CA 2547863 A1 CA2547863 A1 CA 2547863A1 CA 002547863 A CA002547863 A CA 002547863A CA 2547863 A CA2547863 A CA 2547863A CA 2547863 A1 CA2547863 A1 CA 2547863A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- pyridin
- ylethyl
- naphthalen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50907303P | 2003-12-12 | 2003-12-12 | |
| US60/509,073 | 2003-12-12 | ||
| FI20031824A FI20031824A0 (fi) | 2003-12-12 | 2003-12-12 | Uusia yhdisteitä ja niiden käyttö terapiassa |
| FI20031824 | 2003-12-12 | ||
| PCT/FI2004/000750 WO2005056520A1 (en) | 2003-12-12 | 2004-12-09 | Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2547863A1 true CA2547863A1 (en) | 2005-06-23 |
Family
ID=34680375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002547863A Abandoned CA2547863A1 (en) | 2003-12-12 | 2004-12-09 | Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1692099A1 (ja) |
| JP (1) | JP2007513928A (ja) |
| CA (1) | CA2547863A1 (ja) |
| WO (1) | WO2005056520A1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102083427B (zh) | 2008-01-09 | 2014-12-10 | 分子洞察制药公司 | 碳酸酐酶ix的抑制剂 |
| MX2010013354A (es) * | 2008-06-04 | 2010-12-21 | Astrazeneca Ab | Moduladores del receptor de leptina de molecula pequeña. |
| EP2706057B1 (en) | 2008-12-05 | 2016-04-20 | Molecular Insight Pharmaceuticals, Inc. | Bis(imidazolyl)compounds and radionuclide complexes |
| WO2010065906A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer |
| TW201034691A (en) | 2008-12-05 | 2010-10-01 | Molecular Insight Pharm Inc | Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof |
| WO2010147965A2 (en) | 2009-06-15 | 2010-12-23 | Molecular Insight Pharmaceuticals, Inc. | Process for production of heterodimers of glutamic acid |
| WO2013103813A1 (en) | 2012-01-06 | 2013-07-11 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix |
| SG11201505477TA (en) | 2013-01-14 | 2015-08-28 | Molecular Insight Pharm Inc | Triazine based radiopharmaceuticals and radioimaging agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2325741C (en) * | 1998-03-26 | 2007-05-08 | Santen Pharmaceutical Co., Ltd. | Urea derivatives having tnf- .alpha. production inhibitory effects |
| IL156506A0 (en) * | 2001-01-12 | 2004-01-04 | Sod Conseils Rech Applic | Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| US7019109B2 (en) * | 2001-03-16 | 2006-03-28 | The Salk Institute For Bilogical Studies | SSTR1-selective analogs |
-
2004
- 2004-12-09 EP EP04805145A patent/EP1692099A1/en not_active Withdrawn
- 2004-12-09 WO PCT/FI2004/000750 patent/WO2005056520A1/en active Application Filing
- 2004-12-09 CA CA002547863A patent/CA2547863A1/en not_active Abandoned
- 2004-12-09 JP JP2006543564A patent/JP2007513928A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1692099A1 (en) | 2006-08-23 |
| JP2007513928A (ja) | 2007-05-31 |
| WO2005056520A1 (en) | 2005-06-23 |
| WO2005056520A8 (en) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6861858B2 (ja) | Ｓｓａｏ阻害剤 | |
| AU758202B2 (en) | Novel thyroid receptor ligands and method II | |
| CN112292375A (zh) | 取代的烷氧基吡啶基吲哚磺酰胺类 | |
| WO2008110008A1 (en) | Amide derivatives as calcium channel blockers | |
| CN109879877B (zh) | 一种可降解plk1和brd4蛋白的化合物及其应用 | |
| KR20190084063A (ko) | Ｅｚｈ２-매개성 암 치료용 조성물 및 방법 | |
| CA2493660A1 (en) | Process for preparing quinolin antibiotic intermediates | |
| CA2287293A1 (en) | Somatostatin agonists | |
| UA85842C2 (uk) | Похідні бензімідазолу як інгібітори ванілоїдного рецептора 1 (vr1) | |
| JP2007513181A (ja) | 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト | |
| US20070043104A1 (en) | UII-modulating compounds and their use | |
| SK15812000A3 (sk) | Inhibítory enzýmu na premenu endotelínu | |
| CA2547863A1 (en) | Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy | |
| JPH02256658A (ja) | アミノ酸誘導体 | |
| EP1675824B1 (en) | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | |
| US20100048549A1 (en) | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | |
| KR20020013942A (ko) | 아미노벤조산 유도체 | |
| EP1678196B1 (en) | Sulfonylamino-peptidomimetics active on the somatostatin receptor subtypes 4 (sstr4) and 1 (sstr1) | |
| EP4365170A1 (en) | Amide compound and use thereof | |
| US20100004339A1 (en) | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists | |
| WO2005033068A1 (en) | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | |
| EP1864995B1 (en) | Beta-lactamic rgd cyclopeptides containing gamma turns | |
| EP1544201B1 (en) | Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications | |
| ES2352736T3 (es) | Agonistas y antagonistas selectivos del receptor de somatostatina 1 y/o 4. | |
| US20040014676A1 (en) | SRC kinase inhibitors useful for treating osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |